ClinicalTrials.gg
CompletedNCT07257120Updated Jun 23, 2026

KarXT Concentrations in the Breast Milk and Plasma of Lactating Females

A Phase 4 interventional study of Xanomeline/trospium chloride in Healthy Volunteers, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to characterize the PK of xanomeline and trospium in breast milk and plasma in healthy lactating female participants, following multiple oral administration of KarXT in healthy lactating participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteer
  • Pharmacokinetics
  • BMS-986510
  • KarXT
  • Cobenfy
  • Healthy lactating women
03

In context

Lead sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 17 studies on the registry; 8 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants should have a (BMI) of 18.0 kg/m2 to 35.0 kg/m2, inclusive, and body weight ≥ 50 kg (110 lb), at screening.
  • Participants should have well-established lactation (ie, at least 4 weeks postpartum) and can produce stable milk product (ie, approximately 3 oz per 3 hours at screening) using the methods required for the study.
  • Participants should be willing to exclusively pump breast milk throughout the treatment period and during the 24-hour post last dose period of milk collection during the CRU domincile period.
  • Participants should agree not to breastfeed or provide milk to infant until after 96 hours post last dose.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have evidence of organ dysfunction or any deviation from normal in physical examination, vital signs, 12-lead , or clinical laboratory determinations beyond what is consistent with the target population reference ranges as assessed by the investigator.
  • Participants must not have history or presence of clinically significant cardiovascular, pulmonary, renal, hematologic, gastrointestinal (eg, obstructive disorders [including conditions that may decrease GI motility, such as ulcerative colitis, intestinal atony, and myasthenia gravis]), endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.
  • Other protocol defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    KarXT

    Drug: Xanomeline/trospium chloride

Interventions

  • DrugXanomeline/trospium chloride

    Drug pages: Xanomeline · Trospium chloride

    Specified dose on specified days

    Also known as: KarXT, BMS-986510

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax) of KarXT in Milk

    Time frame: Up to Day 7

  2. Time of maximum observed concentration (Tmax) of KarXT in Milk

    Time frame: Up to Day 7

  3. Area under the concentration-time curve from time zero to 12 hours post morning dose [AUC(0-12)] of KarXT in Milk

    Time frame: Up to Day 7

  4. Area under the concentration-time curve from time zero to 24 hours post morning dose [AUC(0-24)] of KarXT in Milk

    Time frame: Up to Day 7

  5. Average concentration (Cavg) of KarXT in Milk

    Time frame: Up to Day 7

  6. Amount of KarXT recovered in milk within 12 hours of dosing [AR(12)]

    Time frame: Up to Day 7

  7. Total amount of KarXT recovered in milk (AR)

    Time frame: Up to Day 7

  8. Milk-plasma ratio of KarXT (M/P)

    Calculated as milk AUC(0-12)/plasma AUC(0-12)

    Time frame: Up to Day 7

Secondary outcomes

  1. Cmax of KarXT in plasma

    Time frame: Up to Day 7

  2. Tmax of KarXT in plasma

    Time frame: Up to Day 7

  3. AUC (0-12) of KarXT in plasma

    Time frame: Up to Day 7

  4. AUC (0-24) of KarXT in plasma

    Time frame: Up to Day 7

  5. Cavg of KarXT in plasma

    Time frame: Up to Day 7

  6. Estimated daily infant dosage of KarXT

    Time frame: Up to Day 7

  7. Relative infant dosage of KarXT

    Time frame: Up to Day 7

  8. Number of participants with Adverse Events (AEs)

    Time frame: Up to Day 34

  9. Number of participants with Serious Adverse Events (SAEs)

    Time frame: Up to Day 34

  10. Number of participants with physical examination abnormalities

    Time frame: Up to Day 7

  11. Number of participants with vital signs abnormalities

    Time frame: Up to Day 7

  12. Number of participants with 12-Lead electrocardiogram (ECG) abnormalities

    Time frame: Up to Day 7

  13. Number of participants with clinical laboratory abnormalities

    Time frame: Up to Day 7

  14. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to Day 7

  15. Number of participants with Adverse Events of Special Interest (AESIs)

    Time frame: Up to Day 34

07

Study locations

1 site
  • Local Institution - 0001
    Las Vegas, Nevada 89113-2246, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Jun 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 2, 2025
StartActual
Jan 9, 2026
Primary completionActual
Jun 8, 2026
CompletionActual
Jun 8, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07257120
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Jan 9, 2026
Primary completion
Jun 8, 2026
Completion
Jun 8, 2026
Last update
Jun 23, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion